Immunohistochemistry PD-L1 for NSCLC

Provide PD-L1 expression predictive biomarker staining/technical proficiency testing to laboratories performing PD-L1 staining in NSCLC for pembrolizumab (Keytruda). The purpose of this program is to assess the laboratory’s ability to specifically detect PD-L1 expression when compared with the commercial assay reference.

For pathologist scoring proficiency testing, please see the program “Immunohistochemistry PD-L1 scoring in NSCLC (TPS)”